Figure 1 | Scientific Reports

Figure 1

From: Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib

Figure 1

Association of single nucleotide polymorphism rs2243250 (IL4) (A) and rs5275 (PTGS2) (B) with cancer-specific survival in metastatic renal cell carcinoma patients treated with sunitinib. Correlation between PTGS2 mRNA expression levels according to rs5275 genotypes (C). Gene expression was determined in patients carrying T allele (TT/TC) or homozygous for C allele. There is a significant difference between the T carriers and CC genotype (P = 0.013).

Back to article page